Frontlight ResearchEarly access
CompletedPhase 3
Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis
Key facts
- Who runs it
- Ukraine Association of Biobank
- Where
- Ukraine1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 700 people enrolled
- Started
- 2 Dec 2018
- Ended
- 30 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Autologous BM MSC
- Record updated
- 22 December 2025
Who can take part
- Age
- 18 years to 69 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Provision of written informed consent for this study by subject or as applicable legal guardians Able to comply with study requirements Еру rates with RVR defined as serum HCV RNA undetectable after 12 month after antiviral therapy
- Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease Subject must have documented history Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection
Who cannot take part
- Positive test result at screening for Hepatitis B surface antigen or anti-human immunodeficiency virus (anti-HIV) antibody HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a study to assess safety and preliminary clinical activity of treatments of liver cirrhosis in patients with caused by Hepatitis C and Hepatitis B or Nonalcoholic Steatohepatitis of Mesenchymal stem cell.
Read full original descriptionShow less
Patients who will be enrolled in the study will be under supervision and monitoring to ensure clinical significance
The group in the trial
- Treatment ArmTreatment being tested
A single dose of 0.5 to 1 x 10\^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
Treatment: Autologous BM MSC
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long Term Follow up Autologous Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis
- Record updated
- 22 December 2025